How has OptimizeRx's increase (decrease) in accounts receivable changed year-over-year?

OptimizeRx's increase (decrease) in accounts receivable decreased by 4.9% year-over-year, from -$5.49M to -$5.76M.

OptimizeRx OPRX Increase (Decrease) in Accounts Receivable

Increase (Decrease) in Accounts Receivable at other companies

Spectral AI, Inc.MDAI

-$82K+79.6%

Veeva SystemsVEEV

——

Claritev CorporationCTEV

——

Other financials

Income statement

See full

Revenue$19.8M-9.5%

Gross profit$14.9M+11.9%

Operating income$396.0K+119%

Net income-$495.0K+77.5%

EPS (diluted)-$0.03+75.0%

Balance sheet

See full

Cash & equivalents$20.2M+21.7%

Total debt$23.7M-27.7%

Total equity$129.6M+11.5%

Total assets$167.3M-0.3%

Cash flow

See full

Operating cash flow-$467.0K-112%

CapEx$21.0K-22.2%

Free cash flow-$488.0K-113%

Valuation

See full

Market cap$107.34M-50.4%

Enterprise value$110.88M-51.4%

P/E15.7×—

P/S1×-1.1×

Profitability

See full

Gross margin70%+14.1pp

Operating margin13.2%—

Net margin6.4%+3.6pp

FCF margin13.4%+4.8pp

Returns & leverage

See full

Return on equity5.6%+3.3pp

Debt / equity0.2×-0.1×

Current ratio5.4×+2.6×

Where this comes from

Reported directly by OptimizeRx in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: OptimizeRx’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about OptimizeRx's increase (decrease) in accounts receivable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OptimizeRx's increase (decrease) in accounts receivable?: OptimizeRx (OPRX) reported increase (decrease) in accounts receivable of -$5.76M in Q1 2026.
How has OptimizeRx's increase (decrease) in accounts receivable changed year-over-year?: OptimizeRx's increase (decrease) in accounts receivable decreased by 4.9% year-over-year, from -$5.49M to -$5.76M.